Integrating Veterinary Diagnostic Laboratories for Emergency Use Testing during Pandemics
The SARS-CoV-2 pandemic showed limitations in human outbreak testing. Veterinary diagnostic laboratories (VDLs) possess capabilities to bolster emergency test capacity. Surveys from 26 participating VDLs found human SARS-CoV-2 testing was mutually beneficial, including One Health benefits. VDLs indicated testing <3.8 million human samples during the pandemic, which included some challenges..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Emerging Infectious Diseases - 30(2024), 2, Seite 386-388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Natasha F. Hodges [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Bioterrorism and preparedness |
|---|
| doi: |
10.3201/eid3002.230562 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ096503025 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096503025 | ||
| 003 | DE-627 | ||
| 005 | 20240413152143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid3002.230562 |2 doi | |
| 035 | |a (DE-627)DOAJ096503025 | ||
| 035 | |a (DE-599)DOAJc3eba3da5ccd47bcbac383378d59c7d1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Natasha F. Hodges |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrating Veterinary Diagnostic Laboratories for Emergency Use Testing during Pandemics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The SARS-CoV-2 pandemic showed limitations in human outbreak testing. Veterinary diagnostic laboratories (VDLs) possess capabilities to bolster emergency test capacity. Surveys from 26 participating VDLs found human SARS-CoV-2 testing was mutually beneficial, including One Health benefits. VDLs indicated testing <3.8 million human samples during the pandemic, which included some challenges. | ||
| 650 | 4 | |a bioterrorism and preparedness | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronaviruses | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a emergency use testing | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a McKenzie Sparrer |e verfasserin |4 aut | |
| 700 | 0 | |a Tyler Sherman |e verfasserin |4 aut | |
| 700 | 0 | |a Treana Mayer |e verfasserin |4 aut | |
| 700 | 0 | |a Danielle R. Adney |e verfasserin |4 aut | |
| 700 | 0 | |a Izabela Ragan |e verfasserin |4 aut | |
| 700 | 0 | |a Molly Carpenter |e verfasserin |4 aut | |
| 700 | 0 | |a Christie Mayo |e verfasserin |4 aut | |
| 700 | 0 | |a Tracy L. Webb |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Emerging Infectious Diseases |d Centers for Disease Control and Prevention, 2003 |g 30(2024), 2, Seite 386-388 |w (DE-627)DOAJ000014966 |x 10806059 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g pages:386-388 |
| 856 | 4 | 0 | |u https://doi.org/10.3201/eid3002.230562 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c3eba3da5ccd47bcbac383378d59c7d1 |z kostenfrei |
| 856 | 4 | 0 | |u https://wwwnc.cdc.gov/eid/article/30/2/23-0562_article |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6040 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6059 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |h 386-388 | ||